anti-Prothrombin (F2) Antikörper

Human Coagulation Factor II (thrombin) (F2) Interaktionspartner

1. Prothrombin gene mutation is rare in Budd-Chiari syndrome patients in India.

2. In HBV-related cirrhosis, the combination of miR (zeige MLXIP Antikörper)-122, AFP (zeige AFP Antikörper) and PIVKA-II enables the identification of patients at higher risk of hepatocellular carcinoma development.

3. Data, including data using network analysis, suggest that angiotensinogen (AGT (zeige AGT Antikörper)), mitogen-activated protein kinase-14 (MAPK14 (zeige MAPK14 Antikörper)), and prothrombin (F2) in placental villous tissues are core factors in early embryonic development; these studies involved proteomics and bioinformatics analysis of altered protein expression in placental villous tissue from early recurrent miscarriage patients in comparison to control tissues.

4. Arg596Gln mutation is a risk factor for Chinese patients with venous thromboembolism due to its moderately decreased clotting activity but strong resistance to antithrombin (zeige SERPINC1 Antikörper) inhibition.

5. The induction of TG by BXPC3 cells was mainly driven by the TF pathway while TG generation triggered by MCF7 cells was also driven by FXII (zeige F12 Antikörper) activation.

6. we were not able to confirm the association between the polymorphisms of f5, f2, and mthfr (zeige MTHFR Antikörper) and pregnancy loss in Bosnian women

7. Platelets were activated in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients, and such activation was at least partially attributed to the thrombin-protease-activated receptors (PARs (zeige EPRS Antikörper)) pathway.

8. The meta-analysis enabled us to underline the importance of DCP (zeige ACE Antikörper) in the refinement of the eligibility criteria of hepatocellular cancer (HCC (zeige FAM126A Antikörper))patients for liver transplant (LT). This information, based on Japanese studies performed in the setting of living-donor LT only, needs further validation in the Western world both in the setting of post-mortem and living-donor LT.

9. HCC (zeige FAM126A Antikörper) [hepatocellular carcinoma] patients who are sero-positive for DCP (zeige ACE Antikörper) [Des (zeige DES Antikörper)-gamma-carboxyprothrombin] and sero-negative for AFP (zeige AFP Antikörper)[Alpha-fetoprotein (zeige AFP Antikörper)] have significantly higher levels of serum ALT[alanine aminotransferase (zeige ALT Antikörper)]; serum ALT levels may be of diagnostic importance in AFP (zeige AFP Antikörper)-negative, HBV-related HCC (zeige FAM126A Antikörper) [hepatitis B virus-related hepatocellular carcinoma] patients.

10. Evaluation of initial thrombin generation is useful to distinguish between beneficial coagulation activation and hazardous haemostatic alteration, and to predict multiorgan dysfunction development and poor outcome in septic patients.

Mouse (Murine) Coagulation Factor II (thrombin) (F2) Interaktionspartner

1. Platelet derived microparticles formed in sepsis are a potent inducer of thrombin generation via phosphatidylserine exposure, and activation of both the intrinsic and extrinsic pathway of coagulation.

2. These findings imply that a thrombin-pericyte interaction in the brain could be a significant mechanism responsible for blood-brain barrier dysfunction under obesity-associated diabetic conditions and thus could represent a therapeutic target for central nervous system complications of diabetes.

3. mutations were introduced into the endogenous fII gene, resulting in expression of prothrombin carrying 3 amino acid substitutions (R157A, R268A, and K281A) to limit activation events to yield only fIIa(Meizothrombin) Homozygous fII(MZ) mice are viable, express fII levels comparable with fII(Wild type) mice, and have reproductive success.

4. Biglycan (zeige BGN Antikörper) plays a protective role during the progression of atherosclerosis in ApoE (zeige APOE Antikörper)-deficient mice by inhibiting thrombin generation.

5. allosteric inhibitor SbO4L targets the glycoprotein Ibalpha (zeige GP1BA Antikörper)-binding and heparin-binding site of thrombin

6. thrombin/PAR-1 (zeige MARK2 Antikörper) interaction regulated MCP-1 (zeige CPT1B Antikörper), TF, MCSF (zeige CSF1 Antikörper) and IL-6 (zeige IL6 Antikörper) production.

7. Observations illustrate the role of thrombin as a pleiotropic atherogenic molecule under conditions of hypercholesterolemia and suggest the utility of its inhibition with locally acting antithrombin (zeige SERPINC1 Antikörper) nanoparticle therapeutics.

8. Thrombin-PAR1 (zeige F2R Antikörper) signaling, via nitric oxide and EPCR (zeige PROCR Antikörper), promotes hematopoietic stem cell (HSC (zeige FUT1 Antikörper)) mobilization.

9. Primary tumor growth by colon cancer cells was reduced by reduction of circulating prothrombin. There were lower mitotic indices and invasiveness. This growth relied upon 2 targets of thrombin-mediated proteolysis, protease: PAR-1 and fibrinogen.

10. Thrombin promotes sustained signaling and inflammatory gene expression through the CDC25 (zeige CDC25C Antikörper) and Ras-associating domains of phospholipase C epsilon (zeige PLCE1 Antikörper).

Cow (Bovine) Coagulation Factor II (thrombin) (F2) Interaktionspartner

1. the weaker rapid interaction between prothrombin and membranes is the most important in vivo when considering the activation of prothrombin at the cell surface.

2. novel pyranosic sulfated (zeige SULF1 Antikörper) arabinan Ab1 exerts its anticoagulant activity on thrombin by a mechanism different from those found previously for other sulfated (zeige SULF1 Antikörper) polysaccharides and glycosaminoglycans

3. Exogenous delivery of thrombin enhances microvascular collateral development in response to ischemic insult, and accelerates tissue reperfusion.

4. the signaling pathways of MAPK (zeige MAPK1 Antikörper), MSK1 (zeige RPS6KA5 Antikörper), and NF-kappaB (zeige NFKB1 Antikörper) play important roles in thrombin-induced iNOS (zeige NOS2 Antikörper) expression in alveolar macrophages

5. High glucose enhances smooth muscle cell responsiveness to thrombin through transcriptional upregulation of PAR-4, mediated via PKC and NFkappaB.

6. Thrombin induces a sustained contraction in the normal pulmonary artery, by activating PAR(1 (zeige F2R Antikörper)) and thereby increasing the sensitivity of the myofilament to Ca(2 (zeige CA2 Antikörper)+).

7. kinetic and structural analysis of interactions between thrombin and the Factor XIII (zeige UGDH Antikörper) activation peptide

8. analysis of staphylocoagulase-mediated bovine prothrombin activation

9. thrombin and factor Xa (zeige F10 Antikörper) diffusion along the heparin molecule explains the effects of extended heparin chain lengths

10. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures.

Zebrafish Coagulation Factor II (thrombin) (F2) Interaktionspartner

1. Prothrombin morpholino-injected zebrafish embryos yielded an early phenotype exhibiting severe abnormalities that later showed occasional bleeding

Rhesus Monkey Coagulation Factor II (thrombin) (F2) Interaktionspartner

1. The great similarity of prothrombin among rhesus, human, and porcine confirm the great value of the pig-to-rhesus xenotransplantation model.

Pig (Porcine) Coagulation Factor II (thrombin) (F2) Interaktionspartner

1. thrombin stimulates transglutaminase activity in articular cartilage by directly cleaving factor XIII (zeige UGDH Antikörper) and by receptor-mediated up-regulation of factor XIII (zeige UGDH Antikörper) synthesis

2. The great similarity of prothrombin among rhesus, human, and porcine confirm the great value of the pig-to-rhesus xenotransplantation model.

3. In conclusion, thrombin activates pro-MMP-2 (zeige MMP2 Antikörper) in the absence of elevated pro-MMP-2 (zeige MMP2 Antikörper) expression and secretion in CSMCs, and thrombin induces CSMC mitogenesis involving its action on MMP-2 (zeige MMP2 Antikörper)

4. Thrombin stimulates swine smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1 (zeige F2R Antikörper), RhoA (zeige RHOA Antikörper), and myocardin (zeige MYOCD Antikörper).